Evaluation and Development of UT28K, a Super-Neutralizing Antibody Therapeutic Candidate
First written in FY2023-Q1. 2 of 6 entries say "Advanced", first in FY2023-Q2. Latest entry: FY2024-Q2.
No other company in this theme has enough history to compare yet.
- FY2024-Q2DroppedAnnual report
「In addition to these pipeline programs, development of UT28K, a super-neutralizing antibody and therapeutic candidate against the virus that causes COVID-19, which the Company had been pursuing with the University of Toyama and Toyama Prefecture, was discontinued in August this year, as previously announced.」
The note explicitly states that development of UT28K was discontinued. - FY2024-Q1RestatedAnnual report
「The Company is pursuing development of this program with the policy of obtaining grants from the government and other sources, and is currently analyzing animal testing to verify the therapeutic effect at the University of Toyama.」
The note reconfirms the policy of pursuing UT28K development with grants from the government and other sources, as well as the analysis stage of animal testing to verify the therapeutic effect at the University of Toyama. - FY2023AdvancedAnnual report
「The Company is currently analyzing animal testing to verify the therapeutic effect at the University of Toyama.」
For UT28K, the Company has progressed from conducting animal testing to verify the therapeutic effect to analyzing the results. - FY2023-Q3RestatedAnnual report
「The Company is currently conducting animal testing to verify the therapeutic effect with a view to securing a grant.」
For UT28K, the Company continues to conduct animal testing to verify the therapeutic effect in pursuit of grant funding. - FY2023-Q2AdvancedAnnual report
「The Company is currently conducting animal testing to verify the therapeutic effect with a view to securing a grant.」
For UT28K, animal testing to verify the therapeutic effect in pursuit of grant funding has progressed from the preparation stage to the implementation stage. - FY2023-Q1First statedAnnual report
「In addition to these pipeline programs, the Company is evaluating UT28K, a super-neutralizing antibody and therapeutic candidate against various variants of the virus that causes COVID-19, together with the University of Toyama and Toyama Prefecture. Animal testing to verify its infection-prevention effect has already been completed, and the Company is currently preparing animal testing to verify its therapeutic effect with a view to securing a grant.」
The Company is evaluating UT28K with the University of Toyama and Toyama Prefecture and has completed animal testing of its infection-prevention effect. It is preparing animal testing to verify its therapeutic effect and pursuing grant funding.